Stage II Colon Cancer: To Treat or Not to Treat?
Being diagnosed with colon cancer can bring about many different feelings. Why me? What are my treatment options? What will the side effects be like? Can I take care of myself? Will this impact how long I live?
A diagnosis of stage II colon cancer has an added concern-do I need chemotherapy after surgery? The answer is, “Maybe.” Studies have not found a clear answer to this question in many cases. Chemotherapy has side effects and we don't want to unnecessarily expose people to chemotherapy unless we are confident it is going to help them.
In stage I colon cancer, surgery to remove the tumor is the only treatment needed. Stage III tumors, when tumors have spread to the lymph nodes, are treated with surgery followed by chemotherapy (called adjuvant chemotherapy; it is given after surgery to reduce the risk of a recurrence of the cancer). This has been shown to lead to improved survival.
Stage II disease falls somewhere in between. An estimated 75% of people with stage II colon cancer will be cancer-free 5 years later, without adjuvant chemotherapy, but 25% will not. Some of these patients may benefit from having chemotherapy after surgery. So, how do we know which patients are most likely to benefit from chemotherapy? That is the million-dollar question.
A tumor is staged using the "TNM" system, which incorporates the Tumor size/depth, presence of cancer in lymph Nodes, and whether or not Metastases are present. Stage II colon cancer includes tumors that are T3N0M0 or T4N0M0.
- T3 tumors invade through the muscularis propria (outer layer of the colon) and into the peri-colorectal tissues (tissue surrounding the colon).
- T4 tumors extend through the colon wall and attach to or invade a nearby structure or organs.
- N0 (N zero) means that no cancer cells were found in the lymph nodes.
- M0 (M zero) means that no metastases are present (no spread to other organs).
- When looking at lymph node status, you also want to know the number of lymph nodes that were examined by the pathologist (we'll discuss more on that later). For example, the report might state "fifteen benign lymph nodes (0/15)" or "tumor seen in sixteen of twenty lymph nodes (16/20)", meaning a total of 15 and 20 nodes were examined, respectively.
You can learn more about colon cancer staging here.
Note: In the past, the Dukes' staging system was commonly used. Dukes B2 and B3 most closely correlate with Stage II in the TNM system. Currently, the Dukes system is no longer used in practice.
Not All Stage II Tumors Are Alike
Though stage II tumors are grouped together, there are some that appear more likely to come back after treatment and may benefit from adjuvant chemotherapy. There are some features of the tumor that increase the chance that the cancer will come back. This means they have a high risk of recurring.
If a tumor has these high-risk features, you should discuss with your provider the risks and benefits of adding chemotherapy after surgery. Each person must make their own educated decisions regarding treatment, based on the information and options given to them by their providers.
What are these high-risk features?
Some high-risk features are
- A T4 tumor – a tumor that has broken through the colon wall and into nearby tissues.
- If there is a bowel perforation or obstruction at the time of diagnosis.
- Grade 3 tumors – these appear very abnormal under the microscope. The grade is reported in the pathology report. You can learn more about all of the above features in the Understanding Pathology article.
- Lymphovascular and perineural invasion –tumor cells in the tiny blood vessels lymph system and nerves around the tumor. This will also be reported in the pathology report.
- Less than 12 lymph nodes were examined by a pathologist.
If you have high-risk features, you should talk with your provider about chemotherapy options. There are some other factors that affect risk and play a role in whether or not to have chemotherapy. These include:
- Prior to surgery for colon cancer, a blood test for CEA (carcinoembryonic antigen) is done. CEA is a substance produced by the cancer cells, called a tumor marker. Elevated levels (CEA>5 ng/ml) prior to surgery may indicate a higher risk of recurrence. After surgery, CEA should return to a normal level. CEA is monitored in the months/years after treatment to look for recurrence, whether or not chemotherapy was received.
- Microsatellite Instability (MSI) status, which is classified as high (H) or low (L). Tumors with MSI-H status are thought to be less aggressive and may not benefit from the addition of chemotherapy.
Genomic profiling, using a gene signature, is an analysis of the level of expression of a group of genes in the tumor tissue, which is then used to predict outcomes.
Genes being looked at are the mutated genes that are a part of the tumor. They are not the genes that you inherited from your parents. Genetics is the study of genes that are inherited and passed on from generation to generation. These genes are responsible for many characteristics, including hair and eye color. Increased risk for certain diseases can also be passed on through genes. BRCA1 and BRCA2 ("breast cancer genes") are an example of this, and women with abnormal versions of these genes are at higher risk of developing breast cancer. The science used in genomic profiling is called genomics. This type of test looks at the genes that make up the tumor and evaluates how they interact and function. It looks at how active various genes are within the tumor, which may influence how the tumor grows and responds to treatment.
A few companies have come up with a panel of tumor genes that can predict how likely the tumor is to recur after surgery. However, the tests have not been shown to be able to predict which tumors will benefit from chemotherapy. The tests can be expensive and may not be covered by insurance. Your provider can send information to your insurance company to request approval. These tests include:
- Oncotype DX Colon Cancer Assay – This test looks at 12 genes to predict the risk of recurrence. The sample is designated as low, intermediate, or high risk.
- ColoPrint – This test looks at 18 genes and designates the tumor as either high or low risk for recurrence.
- GeneFx – This test looks at 482 genes and designates the tumor as low or high risk.
Putting it All Together
As you can see, there are a number of things to think about when treating stage II colon cancer. Studies continue to look at the benefits and risks of treatment and which treatments are superior. The best we can do is look at each patient and their tumor individually.
You and your providers should consider the stage and features of the tumor, your medical history, and your preferences about treatment. As an educated patient, you play a role in this decision-making process and need to make a decision you can feel comfortable with, using all of the information available.
Fotheringham, S., Mozolowski, G. A., Murray, E. M., & Kerr, D. J. (2019). Challenges and solutions in patient treatment strategies for stage II colon cancer. Gastroenterology Report, 7(3), 151-161.
Kannarkatt, J., Joseph, J., Kurniali, P. C., Al-Janadi, A., & Hrinczenko, B. (2017). Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. Journal of oncology practice, 13(4), 233-241.
Meyers, B. M., Cosby, R., Quereshy, F., & Jonker, D. (2017). Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a Cancer Care Ontario systematic review. Clinical Oncology, 29(7), 459-465.
National Comprehensive Cancer Network Guidelines Version 2.2021 Colon Cancer. www.nccn.org
De Dosso, S., Sessa, C., & Saletti, P. (2009). Adjuvant therapy for colon cancer: present and perspectives. Cancer Treat Rev, 35(2), 160-166.
Gangadhar, T., & Schilsky, R. L. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol.
Gill, S. et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol.22, 1797-1806 (2004).
Glas, A.M., et al. Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings Vol 27, No 15S (May 20 Supplement), 2009: 4036.
Halling, K.C., French, A.J. and S.K. McDonnell et al., Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers, J Natl Cancer Inst91 (1999), pp. 1295–1303.
Kerr, D et al. (2009). A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study (abstract 4000). J Clin Oncology, 27(suppl 15s).
Lanza, G, Matteuzzi, M and R. Gafá et al., Chromosome 18q allelic loss and prognosis in stage II and III colon cancer, Int J Cancer79 (1998), pp. 390–395.
Le Voyer, T. E., Sigurdson, E. R., Hanlon, A. L., Mayer, R. J., Macdonald, J. S., Catalano, P. J., et al. (2003). Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol, 21(15), 2912-2919.
Marshall, J. L. Risk assessment in Stage II colorectal cancer. Oncology (Williston Park), 24(1 Suppl 1), 9-13.
McCleary, N. J., & Meyerhardt, J. A. New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient. Oncology (Williston Park), 24(1 Suppl 1), 3-8.
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., et al. (1995). Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol, 13(12), 2936-2943.
O'Connell, J. B., Maggard, M. A., & Ko, C. Y. (2004). Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst, 96(19), 1420-1425.
Quah, H. M., Chou, J. F., Gonen, M., Shia, J., Schrag, D., Landmann, R. G., et al. (2008). Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum, 51(5), 503-507.
Ribic, C. M. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257 (2003).
Salazar, R., et al. Development and validation of a robust high-throughput gene expression test (ColoPrint) for risk stratification of colon cancer Patients. ASCO 2010 GI Cancers Symposium, Abstract #295.
Sargent, D. J. et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J. Clin. Oncol. (Meeting abstracts)29, 4008 (2008).
Schrag, D., Rifas-Shiman, S., Saltz, L., Bach, P. B., & Begg, C. B. (2002). Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol, 20(19), 3999-4005.
Vicuna, B., & Benson, A. B., 3rd. (2007). Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. J Natl Compr Canc Netw, 5(9), 927-936.
Weiser, M. R., Landmann, R. G., Kattan, M. W., Gonen, M., Shia, J., Chou, J., et al. (2008). Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol, 26(3), 380-385.